(NOVC.DE) Stock Price & Overview

FRA:NOVC • DK0060534915

Current stock price

86.34 EUR
-2.03 (-2.3%)
Last:

The current stock price of NOVC.DE is 86.34 EUR. Today NOVC.DE is down by -2.3%. In the past month the price decreased by -49.3%. In the past year, price decreased by -13.99%.

NOVC.DE Key Statistics

52-Week Range85.56 - 185.12
Current NOVC.DE stock price positioned within its 52-week range.
1-Month Range85.56 - 185.12
Current NOVC.DE stock price positioned within its 1-month range.
Market Cap
386.277B
P/E
43.17
Fwd P/E
15.13
EPS (TTM)
2.00
Dividend Yield
N/A

NOVC.DE Stock Performance

Today
-2.3%
1 Week
-53.15%
1 Month
-49.30%
3 Months
-41.00%
Longer-term
6 Months -38.72%
1 Year -13.99%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

NOVC.DE Stock Chart

 / NOVC Daily stock chart

NOVC.DE Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to NOVC.DE. When comparing the yearly performance of all stocks, NOVC.DE is a bad performer in the overall market: 93.76% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NOVC.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to NOVC.DE. NOVC.DE gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NOVC.DE Earnings

Next Earnings DateN/A
Last Earnings DateN/A
PeriodQ2 / 2023
EPS ReportedDKK4.32
Revenue Reported
EPS Surprise -6.63%
Revenue Surprise 97,265.92%

NOVC.DE Forecast & Estimates

32 analysts have analysed NOVC.DE and the average price target is 169.94 EUR. This implies a price increase of 96.83% is expected in the next year compared to the current price of 86.34.

For the next year, analysts expect an EPS growth of 96.77% and a revenue growth 27.56% for NOVC.DE


Analysts
Analysts70.63
Price Target169.94 (96.83%)
EPS Next Y96.77%
Revenue Next Year27.56%

NOVC.DE Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

NOVC.DE Financial Highlights

Over the last trailing twelve months NOVC.DE reported a non-GAAP Earnings per Share(EPS) of 2. The EPS decreased by -32.68% compared to the year before.


Income Statements
Revenue(TTM)201.32B
Net Income(TTM)67.24B
Industry RankSector Rank
PM (TTM) 33.4%
ROA 23.95%
ROE 74.32%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%-26.37%
Sales Q2Q%31.59%
EPS 1Y (TTM)-32.68%
Revenue 1Y (TTM)28.03%

NOVC.DE Ownership

Ownership
Inst OwnersN/A
Shares4.47B
Float1.58B
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About NOVC.DE

Company Profile

NOVC logo image Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

IPO: 1974-05-17

Novo Alle 1

Bagsvaerd DK

Employees: 59337

NOVC Company Website

Phone: 4544448888.0

/ NOVC.DE FAQ

What does NOVC do?

Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.


What is the stock price of today?

The current stock price of NOVC.DE is 86.34 EUR. The price decreased by -2.3% in the last trading session.


What is the dividend status of ?

NOVC.DE does not pay a dividend.


What is the ChartMill technical and fundamental rating of NOVC stock?

NOVC.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


Where is (NOVC.DE) stock traded?

NOVC.DE stock is listed on the Frankfurt Stock Exchange exchange.


Is (NOVC.DE) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NOVC.DE.


What is the ownership structure of (NOVC.DE)?

You can find the ownership structure of (NOVC.DE) on the Ownership tab.